208 related articles for article (PubMed ID: 10631627)
1. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Boyd RA; Stern RH; Stewart BH; Wu X; Reyner EL; Zegarac EA; Randinitis EJ; Whitfield L
J Clin Pharmacol; 2000 Jan; 40(1):91-8. PubMed ID: 10631627
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
4. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
6. Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Srinivas NR
J Clin Pharmacol; 2009 Dec; 49(12):1492-3. PubMed ID: 19955497
[No Abstract] [Full Text] [Related]
7. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
8. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
Hochman JH; Pudvah N; Qiu J; Yamazaki M; Tang C; Lin JH; Prueksaritanont T
Pharm Res; 2004 Sep; 21(9):1686-91. PubMed ID: 15497697
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
Chan LM; Cooper AE; Dudley AL; Ford D; Hirst BH
J Drug Target; 2004; 12(7):405-13. PubMed ID: 15621665
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
[TBL] [Abstract][Full Text] [Related]
12. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062
[TBL] [Abstract][Full Text] [Related]
13. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
[TBL] [Abstract][Full Text] [Related]
14. Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
Kubitza D; Becka M; Roth A; Mueck W
J Int Med Res; 2012; 40(5):1688-707. PubMed ID: 23206451
[TBL] [Abstract][Full Text] [Related]
15. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
16. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM
Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
[TBL] [Abstract][Full Text] [Related]
19. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
20. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
